204 results about "Risk of infection" patented technology

Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment.

Germicidal compositions with enhanced activity towards killing microbiological spores and vetgetative cells comprising certain quaternary ammonium compounds (QACs), phenolic compounds, monohydric alcohols, hydrogen peroxide, iodine, triclocarban, triclosan or combinations thereof with one or more spore coat opening agents. The invention also provides for the application of the germicidal compositions to animate and inanimate surfaces to help kill germs and protect against the risk of infection from bacteria, molds, yeasts, fungi, viruses, and microbiological spores.

A tool is provided for facilitating determining a proper location for an implantable device or medication, and for then delivering the implant to the precise location determined with the tool. To determine the target location, the tool may include a component for testing target locations, such as a stimulating probe for simulating a miniature implantable stimulator. In one embodiment, the tool is used to test a miniature implantable stimulator prior to depositing the implant precisely at the target location. The components of the tool are configured to maintain the implant at the target location while the tool is withdrawn. In one embodiment, a push rod assembly of the tool keeps the implant in position while it retracts the implant holder from around the implant. The ergonomic and light-weight tool leads to reduced surgical time, number and size of incisions, risk of infection, and likelihood of error.

Disclosed herein is a novel tube-in-tube endotracheal tube apparatus that allows for replacement or cleaning of an inner (first) tube without having to re-intubate the patient. The novel endotracheal tube apparatus enables the application of continuous suction or intermittent suction. The endotracheal device also serves to decrease the incidence of ventilator-associated pneumonia (VAP).

Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 μg/kg, and (c) without requiring administration for at least 3 months after the last administration.

A mutant herpesvirus that can be used a recombinant virus vector includes (a) a mutation such that the mutant virus has a reduced ability in comparison with a parent type to cause lysis of an infected cell, and (b) an inactivating mutation in a gene essential for the production of infectious virus. An example is a HSV1 mutant lacking the essential glycoprotein gH gene and having a mutation impairing the function of the gene product VP16. A heterologous gene can be carried at the site of the inactivated essential gene, e.g. a gene suitable for administering gene therapy. The vector has an increased margin of safety over known herpesvirus vectors in respect of incidence of cytopathic effects and/or risk of infection.

Live-attenuated vaccines against Edwardsiella ictaluri or against Pasteurella piscicida are disclosed. Both vaccines are incapable of reversion to virulence, because both are made by deletion mutations in the aroA gene, the purA gene, or both. These vaccines may be used not only to vaccinate fish against Edwardsiella ictaluri or Pasteurela piscicida, but also to serve as vectors to present antigens from other pathogens to the fish, thereby serving as vaccines against other pathogens as well, with no risk of infection by reversion to the virulent form of the pathogen in which the antigen occurs naturally.

Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment.

The disclosed system, apparatuses, methods, and computer-readable media can be used by a computer to establish the security status of another computer before establishing a network connection to it. Responsive to a request message, security state data indicating this status can be incorporated into a response message as one of the first few packets exchanged by computers to establish a network connection. This enables a computer to determine whether the other computer's security status is compliant with its security policy before establishing the network connection, reducing risk of infection by a virus, worm, or the like.

The present invention provides isolated European-like porcine reproductive and respiratory syndrome viruses, polynucleotides, and polypeptides. The present invention also provides methods for making antibodies to the viruses and polypeptides, methods for detecting porcine reproductive and respiratory syndrome viruses, immunogenic compositions, and methods for treating a porcine subject at risk of infection by, or displaying symptoms of, a porcine reproductive and respiratory syndrome virus infection.

The invention provides compositions of influenza proteins, such as matrix and nucleoprotein, that are presented to an individual's immune system as multimeric displays to induce an immune response. The compositions are optionally associated with any type of immunomodulatory compound (IMC) comprising an immunostimulatory sequences (ISS). The invention further provides compositions of influenza matrix and nucleoproteins that can induce cellular and/or humoral immune response. The invention also provides methods of making and using these compositions, e.g., as a vaccine, for ameliorating symptoms associated with infection with influenza virus or for reducing the risk of infection with influenza virus.

The present invention relates to methods for reducing the risk of infection due to surgical or invasive medical procedures. The present invention also relates to methods for preventing infection due to surgical or invasive medical procedures.

A flange extender for an ostomy bag comprises honey. In a preferred embodiment, the flange extender comprises a composition of hydrocolloid and medical grade Manuka honey and at least one release liner. Incorporation of honey into a flange extender provides additional adhesion to the skin of an ostomate and to a flange of an ostomy bag, increased wear time may possible and there may be reduced peristomal skin irritation. These advantages provide increased comfort for a user as well as reduced risk of infection through the antibacterial properties of honey.

The invention discloses an infectious disease infection risk prediction method and device and a storage medium. The method comprises the steps that of first space-time trajectory information of a to-be-detected user is obtained locally from first equipment, then an encrypted target prediction model of infectious disease infection risks is obtained, the first space-time trajectory information is input into the encrypted target prediction model, and an infectious disease infection risk result corresponding to the to-be-detected user is obtained. Obtaining; an encryption prediction model of the infectious disease infection risk is acquired by utilizing the space-time track information of the definite diagnosis user; infection risk detection of the to-be-detected user is realized; whole duringthe detection process, wherein the target prediction model is obtained based on the space-time trajectory information of the infectious disease definite diagnosis user; c. Compared with the prior art, the method has the advantages that the a model is encrypted, the unknown original space-time trajectory of the user is diagnosed, the user to be detected does not need to share the space-time trajectory information, infection risk detection is completed locally, the space-time trajectory information of the user can be protected, and leakage of user privacy is effectively avoided.

An improved wound dressing is described. The wound dressing contains an allograft having at least one layer of human amnion and chorion tissues that has a size and shape appropriate for covering a wound, a base sheet for securing the allograft over the wound, and optionally a support layer to protect the allograft. Methods of preparing the wound dressing and using it in wound healing are also described. The products and methods improve the performance of the wound healing, e.g., by accelerating wound healing, reducing scar formation, inflammation and risk of infection.

The invention discloses a closed type throat swab sampling device. According to the device, the upper end of a handle is connected with a display screen through a connecting shaft, the lower part of the handle is connected with a long plate, the top end of the long plate is connected with a tongue depressor, and the long plate is provided with a sampling cavity and a camera; a fixed valve is arranged at the joint of the long plate and the handle; and a sealing cover is fixedly or movably sleeved on the long plate, and an elastic band is arranged at the middle hole to be tightly bonded with thelong plate. The invention has the advantages that: the device can be used to solve the problem of how to safely and correctly collect throat swab specimens by medical staff for infectious respiratorydiseases, particularly for patients with corona virus disease 2019 at present. Oral and nasal parts of the patient are properly covered in a closed manner, thus avoiding an extremely high risk of infection since the medical staff directly face respiratory tract pathogenic bacteria when collecting throat swab specimens of patients; and a real-time image in the oral cavity is displayed in vitro byleading-in the camera with a light source to the oral cavity, and the medical staff can correctly and quickly acquire an ideal throat swab specimen under the guidance of the real-time image.

A crosslinkable polysaccharide derivative which has in the side chain of polysaccharide at least one active ester group reactive with an active hydrogen-containing group and which forms a crosslinked product through covalent bond between the active ester group and the active hydrogen-containing group upon contact with alkaline water. A composition and a medical treatment material containing the crosslinkable polysaccharide derivative. The crosslinkable polysaccharide derivative produces a high bond strength that meets clinical requirements. It avoids the risk of infection because it is based on a material which is not derived from living organisms. It in itself and its decomposition products have a low level of toxicity because it is formed from a synthetic material. It is biodegradable and bioabsorbable. It can be prepared readily and simply without requiring special apparatus at the time of use.

A light-emitting, antimicrobial tuber, instrument or catheter includes a thin, flexible tube having an optically transparent wall; and a light transmitter configured and arranged to emit light through the tube, which may be ultraviolet C (UVC) irradiation, photodynamic therapy (PDT), violet-blue light therapy, and other light-based therapies. In one embodiment, violet-blue light from 400-500 nm in wavelength, such as 405 nm, for instance, is used. The device is used on a patient and a therapeutic amount of light is administered to the patient, thereby reducing the risk of infections being transmitted from the instrument, tube or catheter to the patient, generally. The device may be configured for use in the urinary tract or as intravascular, and may be indwelling or temporary. Light may be administered for the duration of use or another time period effective to halt, inhibit, or reduce microbial or fungal growth.